(RTTNews) - Molecular Insight Pharma Inc. (MIPI: News ), a development stage bio pharma company, said Monday that its one-year follow-up records of a Phase I dose-escalation clinical study of Azedra showed positive safety profile and durable tumor response in neuroendocrine cancer patients.

As per the data presented at the symposium organised by North American Neuroendocrine Tumor Society, Azedra demonstrated clinical benefit and stabilizing or reducing tumor volumes. The target of the 12-month dose escalation study was to find out the maximum tolerated dose, safety and efficacy of Azedra.

Out of the twenty-one patients treated, three patients reported partial response, 14 recorded stable disease and two reported progressive report.

Edward Coleman, Duke University Medical Center said, "Currently, there are no approved treatments in the United States for patients with metastatic neuroendocrine tumors, so a targeted radiotherapeutic such as Azedra that could provide a more potent, effective therapy would be a significant therapeutic advancement,"
In addition, the company noted that its Phase 2 clinical study of Azedra has received an orphan drug designation and Fast track status from FDA.

MIPI is currently trading at $ 5.60 up $0.21 or 3.90% on a volume of 14,660 thousands of shares on the Nasdaq.

To receive FREE breaking news email alerts for MOLECULAR INSIGHT PHARMA and others in your portfolio

by RTT Staff Writer

For comments and feedback: contact editorial@rttnews.com